15678-99-6Relevant articles and documents
Hayon et al.
, p. 5388,5391 (1971)
Neutral and cationic yttrium alkyl complexes with linked 1,4,7-triazacyclononane-amide monoanionic ancillary ligands: Synthesis and catalytic ethene polymerisation
Bambirra,Van Leusen,Meetsma,Hessen,Teuben
, p. 637 - 638 (2001)
Yttrium dialkyl complexes [N,N′-R2-tacn-N″-(CH2)2 NBut]-Y(CH2SiMe3)2 (R = Me, Pri; tacn = 1,4,7-triazacyclononane) were prepared; when activated with [PhNMe2H]-[B(C6F5)4] these complexes form cationic alkyl species that are active ethene polymerisation catalysts.
METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS
-
Paragraph 849-852, (2021/11/06)
The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB2R Ligands
Qian, Hai-Yan,Wang, Zhi-Long,Chen, Li-Li,Pan, You-Lu,Xie, Xiao-Yu,Xie, Xin,Chen, Jian-Zhong
supporting information, p. 2455 - 2463 (2018/11/23)
Herein we describe the design and synthesis of a new series of heteroarylpyrimidine/heteroaryltriazine derivatives on the basis of quinazoline-2,4(1H,3H)-diones as CB2R-selective ligands using a bioisosterism strategy. An acetamide group was explored to displace the enamine linker of the lead compound for the purpose of stereoisomerism elimination and hydrophilicity increase. As a result, some of the synthesized compounds showed high bioactivity and selectivity for CB2R in calcium mobilization assays, and four displayed CB2R agonist activity, with EC50 values below 30 nm. The compound exhibiting the highest agonist activity toward CB2R (EC50=7.53±3.15 nm) had a selectivity over CB1R of more than 1328-fold. Moreover, structure–activity relationship (SAR) studies indicated that the substituents on the nucleus play key roles in the functionality of a ligand, with one such example demonstrating CB2R antagonist activity. Additionally, molecular docking simulations were conducted with the aim of better understanding of these new derivatives in relation to the structural requirements for agonists/antagonists binding to CB2R.
